Friday, October 31, 2025 10/31/2025

(PQ3) Cellular and Molecular Mechanisms Driving Myeloid Compartment Variation in Human Triple Negative Breast Cancer

Award Number: R01CA219880
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2017
PERIOD OF PERFORMANCE END DATE: 04/30/2023

Group Awards By:

View Award Description

(PQ3) Cellular and Molecular Mechanisms Driving Myeloid Compartment Variation in Human Triple Negative Breast Cancer - PROJECT SUMMARY Numerous studies over the past decade examined the tumor and blood compartment in cancer patients. These studies have added to our understanding of immune alterations in cancer, but have failed to fully explain the functional variation in myeloid antigen presenting cells (mAPCs). We must address this gap before we can begin to fully answer the question posed above because mAPCs control cancer antigen presentation to T cells thereby launching and regulating anti-cancer immunity. The overarching goal of this proposal is to better understand the molecular basis of variation in the immune response to triple negative breast cancer (TNBC) at single cell level. This approach will likely redefine the biology of mAPCs in cancer. We propose a systematic exploration of immune status in blood and tumors in a cohort of 75 TNBC patients with residual cancer. We hypothesize that the variation in transcriptome and function of mAPCs in TNBC patients is linked with specific genomic profiles of their associated cancer cells and contributes to variable response to chemotherapy and disease progression. We propose two specific aims: In Aim 1, we will apply single cell transcriptomics to identify myeloid APC-specific transcriptional profiles in the blood. We will do so at steady state and in response to ex vivo activation with tumor derived factors. This will identify distinct transcriptomics and functional modules that could enable prediction of cell behavior when tumor environments are altered. Gene sets and/or cells defined in blood studies will be applied to tumors to trace these cells using mass spectrometry-based imaging and to examine transcriptional profiles specific to leukocyte infiltrate harvested with macro dissection. In Aim 2, we will examine genes that could be linked with the attraction and differentiation of APCs in the tumor (chemokines and cytokines). We will examine links between cancer genomic aberrations and transcriptional variation in APCs and between the ex vivo response of myeloid APCs to tumor products and in situ transcriptional profiles. We will examine TNBC patient derived xenograft (PDX) tissues established from residual disease to determine cancer-cell intrinsic chemokine/cytokine profiles, and their role in the attraction of myeloid cells when implanted in humanized mice. CRISPR/Cas9 editing will be applied to cancer cells to generate variants and to verify links with the variation in the APCs compartment and impact on tumor progression and metastasis. These studies will lay a foundation for better understanding how immune variations contribute to the aggressiveness of TNBC and enable the identification of potential actionable therapeutic targets in residual disease.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$9 )
2024	2021	JACKSON LABORATORY	600 MAIN ST	BAR HARBOR	ME	04609	HANCOCK	USA	Cancer Treatment Research	000	5	1/12/2024	NON-COMPETING CONTINUATION	-$9
														Subtotal = -$9

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2021	THE JACKSON LABORATORY	600 MAIN ST	BAR HARBOR	ME	04609	HANCOCK	USA	Cancer Treatment Research	000	5	11/16/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $675,289 )
2021	2021	THE JACKSON LABORATORY	600 MAIN ST	BAR HARBOR	ME	04609	HANCOCK	USA	Cancer Treatment Research	000	5	7/19/2021	NON-COMPETING CONTINUATION	$675,289
														Subtotal = $675,289

Issue Date FY: 2020 ( Subtotal = $670,182 )
2020	2020	THE JACKSON LABORATORY	600 MAIN ST	BAR HARBOR	ME	04609	HANCOCK	USA	Cancer Treatment Research	000	4	7/31/2020	NON-COMPETING CONTINUATION	$670,182
														Subtotal = $670,182

Issue Date FY: 2019 ( Subtotal = $650,064 )
2019	2019	THE JACKSON LABORATORY	600 MAIN ST	BAR HARBOR	ME	04609	HANCOCK	USA	Cancer Treatment Research	000	3	7/4/2019	NON-COMPETING CONTINUATION	$650,064
														Subtotal = $650,064

Issue Date FY: 2018 ( Subtotal = $670,182 )
2018	2018	THE JACKSON LABORATORY	600 MAIN ST	BAR HARBOR	ME	04609	HANCOCK	USA	Cancer Treatment Research	000	2	7/25/2018	NON-COMPETING CONTINUATION	$670,182
														Subtotal = $670,182

Issue Date FY: 2017 ( Subtotal = $697,539 )
2017	2017	THE JACKSON LABORATORY	600 MAIN ST	BAR HARBOR	ME	04609	HANCOCK	USA	Cancer Treatment Research	000	1	8/24/2017	NEW	$697,539
														Subtotal = $697,539

Grand Total All Awards = $3,363,247

Top

All Categories

About

Search

Reports

Data Submission

Award Information

(PQ3) Cellular and Molecular Mechanisms Driving Myeloid Compartment Variation in Human Triple Negative Breast Cancer

Award Number: R01CA219880

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2017

PERIOD OF PERFORMANCE END DATE: 04/30/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer